CIP
LGND icon

Cornerstone Investment Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Cornerstone Investment Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$440K Buy
2,205
+507
+30% +$100K 0.02% 76
2025
Q4 		$321K Buy
1,698
+1
+0.1% +$192 0.01% 98
2025
Q3 		$301K Sell
1,697
-128
-7% -$19K 0.01% 113
2025
Q2 		$207K Buy
+1,825
New +$195K 0.01% 159
2025
Q1 		– Sell
-1,984
Closed -$213K – 233
2024
Q4 		$213K Buy
+1,984
New +$224K 0.01% 183

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Cornerstone Investment Partners's LGND Position: Q1 2026 in Review

Cornerstone Investment Partners increased its Ligand Pharmaceuticals (LGND) stake by 30% in Q1 2026, buying an estimated $100K and bringing the position to 2,205 shares worth $440K. The position accounts for 0.02% of the portfolio, ranked #76.

Cornerstone Investment Partners first reported a position in LGND in Q4 2024 and has held it in 5 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Cornerstone Investment Partners held 2,205 shares of Ligand Pharmaceuticals worth $440K as of Q1 2026.
  • Cornerstone Investment Partners bought 507 Ligand Pharmaceuticals shares in Q1 2026, an estimated $100K.
  • Ligand Pharmaceuticals made up 0.02% of Cornerstone Investment Partners's portfolio in Q1 2026, its #76 holding.
  • Cornerstone Investment Partners first reported a position in Ligand Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Cornerstone Investment Partners's 13F filing for Q1 2026, filed 8 May 2026.